Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Fatty acyl-CoA reductase 2 (FAR2) is an enzyme that catalyzes the reduction of saturated (but not unsaturated) C16 or C18 fatty acyl-CoA substrates to their corresponding fatty alcohols[1][2][4]. This process is critical for fatty alcohol biosynthesis and lipid metabolism, with implications for cellular membrane composition and signaling. Genetic or functional changes in FAR2 have been implicated in the development of mesangial matrix expansion and chronic kidney disease[3][5]. FAR2 belongs to the short chain dehydrogenase/reductase (SDR) family and is known by several alternative names and symbols. No direct approved drugs or safety concerns have been commonly described for FAR2 based on currently available biomedical data.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Fatty acyl-CoA reductase 2 (FAR2).